Sun Pharma sees all time high market share and prescription trends in the US for key specialty products and remains upbeat on the prospects of deuruxolitinib for alopecia areata. The company also isn’t ruling out a potential comeback, at least not yet, for a higher dose version of the JAK1/2 inhibitor.

Only two breakthrough-designated novel agents remain on the US FDA drugs center’s 2023 user fee calendar, while CBER stacks up on vaccines and gene therapies under both BTD and RMAT programs.

Japan’s largest biopharma R&D hub has been in active discussions with Korean bioventures for possible collaboration in the cell and gene therapy area. The idea, also backed by the Korean government, started with a paradigm shift during the pandemic.

Sun stays “tentative” about a large exposure in the biosimilars segment while also outlining its approach to commercialize some diverse pipeline assets including an early stage GLP-1 receptor agonist.